Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

123

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

December 31, 2017

Study Completion Date

August 31, 2020

Conditions
Neuroendocrine Tumors
Interventions
DRUG

Lenvatinib

Trial Locations (22)

8036

Universitätsklinik für Innere Medizin, Graz

20141

Istituto Europeo di Oncologia - Unità di Oncologia Medica Gastrointestinale e Tumori Neuroendocrini, Milan

28034

Hospital Universitario Ramón y Cajal, Madrid

28041

Hospital Universitario 12 de Octubre, Madrid

28046

Hospital Universitario la Paz, Madrid

29010

Hospital Virgen de la Victoria, Málaga

33006

Hospital Central de Asturias, Oviedo

39011

Hospital Marqués de Valdecilla, Santander

41124

AOU Policlinico di Modena - DH Oncologico, Modena

50009

Hospital Miguel Servet, Zaragoza

50139

Azienda Ospedaliero Universitaria Careggi - SC di Oncologia, Florence

a-1090

Medizinische Universität Wien, Vienna

Unknown

Spedali Civili di Brescia, Brescia

Instituto Oncologico Mediterraneo, Catania

IRST of Meldola, Meldola

IRCCS Napoli, Napoli

Hospital Universatorio de Verona, Verona

Hospital de Donostia, Donostia / San Sebastian

08035

Hospital Universitario Vall Hebrón, Barcelona

08908

ICO Hospitalet, L'Hospitalet de Llobregat

G12 0YN

Beatson Oncology Centre Gartnavel General Hospital, Glasgow

M20 4BX

Christie Hospital, Manchester, Manchester

All Listed Sponsors
collaborator

Eisai Limited

INDUSTRY

collaborator

Experior S.L.

UNKNOWN

lead

Grupo Espanol de Tumores Neuroendocrinos

OTHER

NCT02678780 - Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter